Tau plasma levels in subjective cognitive decline: Results from the DELCODE study

Stephan Müller; Oliver Preische; Jens C. Göpfert; Viviana A.Carcamo Yañez; Thomas O. Joos; Henning Boecker; Emrah Düzel; Peter Falkai; Josef Priller; Katharina Buerger; Cihan Catak; Daniel Janowitz; Michael T. Heneka; Frederic Brosseron; Peter Nestor; Oliver Peters; Felix Menne; Carola G. Schipke; Anja Schneider; Annika Spottke; Klaus Fließbach; Ingo Kilimann; Stefan Teipel; Michael Wagner; Jens Wiltfang; Frank Jessen; Christoph Laske

doi:10.1038/s41598-017-08779-0

Tau plasma levels in subjective cognitive decline: Results from the DELCODE study

Stephan Müller, Oliver Preische, Jens C. Göpfert, Viviana A.Carcamo Yañez, Thomas O. Joos, Henning Boecker, Emrah Düzel, Peter Falkai, Josef Priller, Katharina Buerger, Cihan Catak, Daniel Janowitz, Michael T. Heneka, Frederic Brosseron, Peter Nestor, Oliver Peters, Felix Menne, Carola G. Schipke, Anja Schneider, Annika SpottkeKlaus Fließbach, Ingo Kilimann, Stefan Teipel, Michael Wagner, Jens Wiltfang, Frank Jessen, Christoph Laske

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. Much less is known whether increased tau plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline (SCD). In the present study we measured tau plasma levels in 111 SCD patients and 134 age- and gender-matched cognitively healthy controls participating in the DZNE (German Center for Neurodegenerative Diseases) longitudinal study on cognition and dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive, single-molecule array (Simoa) technology. We found no significant different tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, gender, and education (p = 0.137). In addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p = 0.634), tau (r = -0.179; p = 0.240), and p-tau181 (r = -0.208; p = 0.171) cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with available CSF. In conclusion, plasma tau is not increased in SCD patients. In addition, the lack of correlation between tau in plasma and CSF in the examined cohort suggests that tau levels are affected by different factors in both biofluids.

Original language	English
Article number	9529
Journal	Scientific Reports
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41598-017-08779-0
State	Published - 1 Dec 2017
Externally published	Yes

Access to Document

10.1038/s41598-017-08779-0

Cite this

Müller, S., Preische, O., Göpfert, J. C., Yañez, V. A. C., Joos, T. O., Boecker, H., Düzel, E., Falkai, P., Priller, J., Buerger, K., Catak, C., Janowitz, D., Heneka, M. T., Brosseron, F., Nestor, P., Peters, O., Menne, F., Schipke, C. G., Schneider, A., ... Laske, C. (2017). Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Scientific Reports, 7(1), Article 9529. https://doi.org/10.1038/s41598-017-08779-0

@article{d89f79af80504d4183798cec5dab8282,

title = "Tau plasma levels in subjective cognitive decline: Results from the DELCODE study",

abstract = "Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. Much less is known whether increased tau plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline (SCD). In the present study we measured tau plasma levels in 111 SCD patients and 134 age- and gender-matched cognitively healthy controls participating in the DZNE (German Center for Neurodegenerative Diseases) longitudinal study on cognition and dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive, single-molecule array (Simoa) technology. We found no significant different tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, gender, and education (p = 0.137). In addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p = 0.634), tau (r = -0.179; p = 0.240), and p-tau181 (r = -0.208; p = 0.171) cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with available CSF. In conclusion, plasma tau is not increased in SCD patients. In addition, the lack of correlation between tau in plasma and CSF in the examined cohort suggests that tau levels are affected by different factors in both biofluids.",

author = "Stephan M{\"u}ller and Oliver Preische and G{\"o}pfert, {Jens C.} and Ya{\~n}ez, {Viviana A.Carcamo} and Joos, {Thomas O.} and Henning Boecker and Emrah D{\"u}zel and Peter Falkai and Josef Priller and Katharina Buerger and Cihan Catak and Daniel Janowitz and Heneka, {Michael T.} and Frederic Brosseron and Peter Nestor and Oliver Peters and Felix Menne and Schipke, {Carola G.} and Anja Schneider and Annika Spottke and Klaus Flie{\ss}bach and Ingo Kilimann and Stefan Teipel and Michael Wagner and Jens Wiltfang and Frank Jessen and Christoph Laske",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41598-017-08779-0",

language = "English",

volume = "7",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Müller, S, Preische, O, Göpfert, JC, Yañez, VAC, Joos, TO, Boecker, H, Düzel, E, Falkai, P, Priller, J, Buerger, K, Catak, C, Janowitz, D, Heneka, MT, Brosseron, F, Nestor, P, Peters, O, Menne, F, Schipke, CG, Schneider, A, Spottke, A, Fließbach, K, Kilimann, I, Teipel, S, Wagner, M, Wiltfang, J, Jessen, F & Laske, C 2017, 'Tau plasma levels in subjective cognitive decline: Results from the DELCODE study', Scientific Reports, vol. 7, no. 1, 9529. https://doi.org/10.1038/s41598-017-08779-0

TY - JOUR

T1 - Tau plasma levels in subjective cognitive decline

T2 - Results from the DELCODE study

AU - Müller, Stephan

AU - Preische, Oliver

AU - Göpfert, Jens C.

AU - Yañez, Viviana A.Carcamo

AU - Joos, Thomas O.

AU - Boecker, Henning

AU - Düzel, Emrah

AU - Falkai, Peter

AU - Priller, Josef

AU - Buerger, Katharina

AU - Catak, Cihan

AU - Janowitz, Daniel

AU - Heneka, Michael T.

AU - Brosseron, Frederic

AU - Nestor, Peter

AU - Peters, Oliver

AU - Menne, Felix

AU - Schipke, Carola G.

AU - Schneider, Anja

AU - Spottke, Annika

AU - Fließbach, Klaus

AU - Kilimann, Ingo

AU - Teipel, Stefan

AU - Wagner, Michael

AU - Wiltfang, Jens

AU - Jessen, Frank

AU - Laske, Christoph

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. Much less is known whether increased tau plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline (SCD). In the present study we measured tau plasma levels in 111 SCD patients and 134 age- and gender-matched cognitively healthy controls participating in the DZNE (German Center for Neurodegenerative Diseases) longitudinal study on cognition and dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive, single-molecule array (Simoa) technology. We found no significant different tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, gender, and education (p = 0.137). In addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p = 0.634), tau (r = -0.179; p = 0.240), and p-tau181 (r = -0.208; p = 0.171) cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with available CSF. In conclusion, plasma tau is not increased in SCD patients. In addition, the lack of correlation between tau in plasma and CSF in the examined cohort suggests that tau levels are affected by different factors in both biofluids.

AB - Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. Much less is known whether increased tau plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline (SCD). In the present study we measured tau plasma levels in 111 SCD patients and 134 age- and gender-matched cognitively healthy controls participating in the DZNE (German Center for Neurodegenerative Diseases) longitudinal study on cognition and dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive, single-molecule array (Simoa) technology. We found no significant different tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, gender, and education (p = 0.137). In addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p = 0.634), tau (r = -0.179; p = 0.240), and p-tau181 (r = -0.208; p = 0.171) cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with available CSF. In conclusion, plasma tau is not increased in SCD patients. In addition, the lack of correlation between tau in plasma and CSF in the examined cohort suggests that tau levels are affected by different factors in both biofluids.

UR - http://www.scopus.com/inward/record.url?scp=85028401474&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-08779-0

DO - 10.1038/s41598-017-08779-0

M3 - Article

C2 - 28842559

AN - SCOPUS:85028401474

SN - 2045-2322

VL - 7

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 9529

ER -

Tau plasma levels in subjective cognitive decline: Results from the DELCODE study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this